Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19

References

• Accelrys. (2009). Accelrys Discovery Studio 2.5. Accelrys.
   Google Scholar
• Alexpandi, R., Mesquita, J. F. D., Pandian, S. K., & Ravi, A. V. (2020). Quinolines-based SARS-CoV-2 3CLpro and RdRp inhibitors and spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: An in silico analysis. Frontiers in Microbiology, 11, 1796–1811. https://doi.org/10.3389/fmicb.2020.01796
   PubMed Web of Science ®Google Scholar
• Arabi, Y. M., Fowler, R., & Hayden, F. G. (2020). Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Medicine, 46(2), 315–328. https://doi.org/10.1007/s00134-020-05943-5
   PubMed Web of Science ®Google Scholar
• Balaramnavar, V. M., Ahmad, K., Saeed, M., Ahmad, I., Kamal, M., & Jawed, T. (2020). Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 Mpro. RSC Advances, 10(66), 40264–40275. https://doi.org/10.1039/D0RA06038K
   PubMed Web of Science ®Google Scholar
• Cannalire, R., Cerchia, C., Beccari, A. R., & Di Leva, F. S. (2020). Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: State of the art and future opportunities. Journal of Medicinal Chemistry.
   PubMed Web of Science ®Google Scholar
• Cava, C., Bertoli, G., & Castiglioni, I. (2020). In silico discovery of candidate drugs against Covid-19. Viruses, 12, 404–418. https://doi.org/10.3390/v12040404
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (2020). Retrived May 10, 2020, from https://www.cdc.gov/coronavirus/types.html
   Google Scholar
• Chenthamarakshan, V., Das, P., Hoffman, S. C., Strobelty, H., Padhi, I., Lim, K. W., Hoovery, B., Manicaz, M., Bornz, J., Lainoz, T., & Mojsilovic, A. (2020). CogMol: Target-specific and selective drug design for COVID-19 using deep generative models. arXiv preprint, arXiv:2004.01215.
   Google Scholar
• Chu, C. M., Cheng, V. C., Hung, I. F., Wong, M. M., Chan, K. H., & Chan, K. S. (2004). Role of lopinavir/ritonavir in thetreatment of SARS: Initial virological and clinical findings. Thorax, 59(3), 252–256. https://doi.org/10.1136/thorax.2003.012658
   PubMed Web of Science ®Google Scholar
• Costanzo, M., De Giglio, M., & Roviello, G. N. (2020). SARS-CoV-2: Recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Current Medicinal Chemistry, 27(27), 4536–4541. https://doi.org/10.2174/0929867327666200416131117
   PubMed Web of Science ®Google Scholar
• de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014). Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrobial Agents and Chemotherapy, 58(8), 4875–4884. https://doi.org/10.1128/AAC.03011-14
   PubMed Web of Science ®Google Scholar
• Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., Johansen, L. M., Lear-Rooney, C. M., Glass, P. J., Hensley, L. E., & Frieman, M. B. (2014). Repurposing of clinically developed drugs for treatment of Middle East Respiratory Syndrome coronavirus infection. Antimicrobial Agents and Chemotherapy, 58(8), 4885–4893. https://doi.org/10.1128/AAC.03036-14
   PubMed Web of Science ®Google Scholar
• Elfiky, A. A. (2020). Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences, 248, 117477. https://doi.org/10.1016/j.lfs.2020.117477
   PubMed Web of Science ®Google Scholar
• Elfiky, A. A. (2021). SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective. Journal of Biomolecular Structure and Dynamics, 39(9), 3204–3212.
   PubMed Web of Science ®Google Scholar
• Fayyazi, N., Esmaeili, S., Taheri, S., Ghasemi, J. B., & Scotti, L. (2019). Pharmacophore modeling, synthesis, scaffold hopping and biological β-Hematin inhibition interaction studies for anti-malaria compounds. Current Topics in Medicinal Chemistry, 142, 94–113.
   Google Scholar
• Fayyazi, N., Fassihi, A., Esmaeili, S., Taheri, S., Ghasemi, J. B., & Saghaie, L. (2020). Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2. International Journal of Biological Macromolecules, 142, 94–101. https://doi.org/10.1016/j.ijbiomac.2019.09.077
   PubMed Web of Science ®Google Scholar
• Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang, L., Ge, J., Zheng, L., Zhang, Y., Wang, H., Zhu, Y., Zhu, C., Hu, T., Hua, T., Zhang, B., … Rao, Z. (2020). Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science (New York, N.Y.), 368(6492), 779–782. https://doi.org/10.1126/science.abb7498
   PubMed Web of Science ®Google Scholar
• Gong, P., & Peersen, O. B. (2010). Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase. Proceedings of the National Academy of Sciences of the United States of America, 107(52), 22505–22510. https://doi.org/10.1073/pnas.1007626107
   PubMed Web of Science ®Google Scholar
• Grzybowski, B. A., Ishchenko, A. V., Shimada, J., & Shakhnovich, E. I. (2002). From knowledge-based potentials to combinatorial lead design in silico. Accounts of Chemical Research, 35(5), 261–269. https://doi.org/10.1021/ar970146b
   PubMed Web of Science ®Google Scholar
• Gupta, S., Fallarero, A., Järvinen, P., Karlsson, D., Johnson, M. S., Vuorela, P. S., & Mohan, C. G. (2011). Discovery of dual binding site acetylcholinesterase inhibitors identified by pharmacophore modeling and sequential virtual screening techniques. Bioorganic & Medicinal Chemistry Letters, 21(4), 1105–1112. https://doi.org/10.1016/j.bmcl.2010.12.131
   PubMed Web of Science ®Google Scholar
• Harrison, C. (2020). Coronavirus puts drug repurposing on the fast track. Nature Biotechnology, 38(4), 379–391. https://doi.org/10.1038/d41587-020-00003-1
   PubMed Web of Science ®Google Scholar
• Hauke, J., Achter, S., & Meyer, M. (2020). Theory development via replicated simulations and the added value of standards. Journal of Artificial Societies and Social Simulation, 23(1), 12. https://doi.org/10.18564/jasss.4219
   Web of Science ®Google Scholar
• Hoffman, R. L., Kania, R. S., Brothers, M. A., Davies, J. F., Ferre, R. A., Gajiwala, K. S., He, M., Hogan, R. J., Kozminski, K., Li, L. Y., Lockner, J. W., Lou, J., Marra, M. T., Mitchell, L. J., Murray, B. W., Nieman, J. A., Noell, S., Planken, S. P., Rowe, T., … Taggart, B. (2020). Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. Journal of Medicinal Chemistry, 63(21), 12725–12747. https://doi.org/10.1021/acs.jmedchem.0c01063
   PubMed Web of Science ®Google Scholar
• Horvath, D., Orlov, A., Osolodkin, D. I., Ishmukhametov, A. A., Marcou, G., & Varnek, A. (2020). A chemographic audit of anti-coronavirus structure-activity information from public databases (ChEMBL). Molecular Informatics, 39(12), 2000080. https://doi.org/10.1002/minf.202000080
   PubMed Web of Science ®Google Scholar
• Huang, J., Song, W., Huang, H., & Sun, Q. (2020). Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: FROM mechanistic studies to clinical trials for COVID-19. Journal of Clinical Medicine, 9, 1131. https://doi.org/10.3390/jcm9041131
   PubMed Web of Science ®Google Scholar
• Iftikhar, H., Ali, H. N., Farooq, S., Naveed, H., & Shahzad-Ul-Hussan, S. (2020). Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach. Computers in Biology and Medicine, 122, 103848–103856. https://doi.org/10.1016/j.compbiomed.2020.103848
   PubMed Web of Science ®Google Scholar
• Kandeel, M., & Al-Nazawi, M. (2020). Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sciences, 251, 117627. https://doi.org/10.1016/j.lfs.2020.117627
   PubMed Web of Science ®Google Scholar
• Kirchdoerfer, R. N., & Ward, A. B. (2019). Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nature Communications, 10(1), 2342–2342. https://doi.org/10.1038/s41467-019-10280-3
   PubMed Web of Science ®Google Scholar
• Kokic, G., Hillen, H. S., Tegunov, D., Dienemann, C., Seitz, F., Schmitzova, J., Farnung, L., Siewert, A., Höbartner, C., & Cramer, P. (2021). Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nature Communications, 12(1), 279–279. https://doi.org/10.1038/s41467-020-20542-0
   PubMed Web of Science ®Google Scholar
• Kumar, V., Tan, K.-P., Wang, Y.-M., Lin, S.-W., & Liang, P.-H. (2016). Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorganic & Medicinal Chemistry, 24(13), 3035–3042. https://doi.org/10.1016/j.bmc.2016.05.013
   PubMed Web of Science ®Google Scholar
• Kumar, Y., Singh, H., & Patel, C. N. (2020). In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Journal of Infection and Public Health, 13(9), 1210–1223. https://doi.org/10.1016/j.jiph.2020.06.016
   PubMed Web of Science ®Google Scholar
• Li, G., & Clercq, E. (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews. Drug Discovery, 19(3), 149–150. https://doi.org/10.1038/d41573-020-00016-0
   PubMed Web of Science ®Google Scholar
• Li, R., Su, X., Chen, Z., Huang, W., Wang, Y., Wang, K., Lin, B., Wang, J., & Cheng, M. (2015). Structure-based virtual screening and ADME/T-based profiling for low molecular weight chemical starting points as p21 activated kinase 4 inhibitors. RSC Advances, 5(30), 23202–23232. https://doi.org/10.1039/C4RA16963H
   Web of Science ®Google Scholar
• Li, X., He, Z., Chen, L., Li, Y., Li, Q., Zhao, S., Tao, Z., Hu, W., Qin, L., & Chen, X. (2011). Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo. Parasitology Research, 109(6), 1519–1524. https://doi.org/10.1007/s00436-011-2427-z
   PubMed Web of Science ®Google Scholar
• Liang-Qin, G., Jing, X. U., & Shao-Dong, C. (2020). In silico screening of potential chinese herbal medicine against COVID-19 by targeting SARS-CoV-2 3CLpro and angiotensin converting enzyme II using molecular docking. Chinese Journal of Integrative Medicine, 26, 527–532.
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. (2004). Lead- and drug-like compounds: The rule-of-five revolution. Drug Discovery Today. Technologies, 1(4), 337–341.
   PubMedGoogle Scholar
• Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., … Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet (London, England), 395(10224), 565–574. https://doi.org/10.1016/S0140-6736(20)30251-8
   PubMed Web of Science ®Google Scholar
• Ma, X. H., Wang, R., Yang, S. Y., Li, Z. R., Xue, Y., Wei, Y. C., Low, B. C., Chen, Y. Z. (2008). Evaluation of virtual screening performance of support vector machines trained by sparsely distributed active compounds. Journal of Chemical Information and Modeling, 48, 1227–1237. https://doi.org/10.1016/j.ddtec.2004.11.007
   PubMed Web of Science ®Google Scholar
• Macchiagodena, M., Pagliai, M., & Procacci, P. (2020). Identification of potential binders of the main protease 3CLpro of the COVID-19 via structure-based ligand design and molecular modeling. Chemical Physics Letters, 750, 137489–137493. https://doi.org/10.1016/j.cplett.2020.137489
   PubMed Web of Science ®Google Scholar
• Madelain, V., Guedj, J., Mentré, F., Huyen Nguyen, T. T., Jacquot, F., & Oestereich, L. (2017). Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. Antimicrobial Agents and Chemotherapy, 61, e01305-16. https://doi.org/10.1128/AAC.01305-16
   PubMed Web of Science ®Google Scholar
• Mansour, M. A., AboulMagd, A. M., & Abdel-Rahman, H. M. (2020). Quinazoline-Schiff base conjugates: In silico study and ADMET predictions as multitarget inhibitors of coronavirus (SARS-CoV-2) proteins. RSC Advances, 10(56), 34033–34045. https://doi.org/10.1039/D0RA06424F
   PubMed Web of Science ®Google Scholar
• Maurya, V. K., Kumar, S., Bhatt, L. B., & Saxena, S. K. (2020). Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection. Journal of Biomolecular Structure and Dynamics, 2020, 1–17.
   Google Scholar
• Mc Tigue, M., Murray, B. W., Chen, J. H., Deng, Y. L., Solowiej, J., & Kania, R. S. (2012). Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 109(45), 18281–18289. https://doi.org/10.1073/pnas.1207759109
   PubMed Web of Science ®Google Scholar
• Muralidharan, N., Sakthivel, R., Velmurugan, D., & Gromiha, M. M. (2020). Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19. Journal of Biomolecular Structure and Dynamics, 16, 1–6.
   Web of Science ®Google Scholar
• Ntie-Kang, F. (2013). An in silico evaluation of the ADMET profile of the Streptome DB database. Springer Plus, 2, 353. https://doi.org/10.1186/2193-1801-2-353
   PubMedGoogle Scholar
• Ngo, S. T., Pham, N. Q. A., Le, L. T., Pham, D., & Vu, V. V. (2020). Computational determination of potential inhibitors of SARS-CoV-2 main protease. Journal of Chemical Information and Modeling, 60(12), 5771–5780. https://doi.org/10.1021/acs.jcim.0c00491
   PubMed Web of Science ®Google Scholar
• Nosengo, N. (2016). Can you teach old drugs new tricks? Nature, 534(7607), 314–316. https://doi.org/10.1038/534314a
   PubMed Web of Science ®Google Scholar
• Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nature Reviews. Drug Discovery, 10(6), 428–438. https://doi.org/10.1038/nrd3405
   PubMed Web of Science ®Google Scholar
• Pant, S., Singh, M., Ravichandiran, V., Murty, U. S. N., & Srivastav, H. K. (2020). Peptide-like and small-molecule inhibitors against Covid-19. Journal of Biomolecular Structure and Dynamics. https://doi.org/10.1080/07391102.2020.1757510
   Google Scholar
• Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., & Pirmohamed, M. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews. Drug Discovery, 18(1), 41–58. https://doi.org/10.1038/nrd.2018.168
   PubMed Web of Science ®Google Scholar
• Saeed, M., Saeed, A., Alam, M. J., & Alreshidi, M. (2021). Receptor-based pharmacophore modeling in the search for natural products for COVID-19 Mpro. Molecules, 26, 1549. https://doi.org/10.3390/molecules26061549
   PubMed Web of Science ®Google Scholar
• Sisk, J. M., & Frieman, M. B. (2015). Screening of FDA-approved drugs for treatment of emerging pathogens. ACS Infectious Diseases, 1(9), 401–402. https://doi.org/10.1021/acsinfecdis.5b00089
   PubMed Web of Science ®Google Scholar
• Sneha, P., Tyagi, A., Jose, V., Jane, M., Krishna, K., & Gopi, M. C. (2016). Integration of common feature pharmacophore modeling and in vitro study to identify potent AChE inhibitors. Medicinal Chemistry Research, 25(12), 2965–2975. https://doi.org/10.1007/s00044-016-1716-6
   Web of Science ®Google Scholar
• Stamos, J., Sliwkowski, M. X., & Eigenbrot, C. (2002). Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. The Journal of Biological Chemistry, 277(48), 46265–46272. https://doi.org/10.1074/jbc.M207135200
   PubMed Web of Science ®Google Scholar
• Stasiulewicz, A., Maksymiuk, A. W., Nguyen, M. L., Bełza, B., & Sulkowska, J. I. (2021). SARS-CoV-2 papain-like protease potential inhibitors—In silico quantitative assessment. International Journal of Molecular Sciences, 22, 3957–3987. https://doi.org/10.3390/ijms22083957
   PubMed Web of Science ®Google Scholar
• Sunseri, J., & Koes, D. R. (2016). Pharmit: Interactive exploration of chemical space. Nucleic Acids Research, 44, 442–448. https://doi.org/10.1093/nar/gkw287
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. (2021). Retrieved June 18, 2021, from https://www.fda.gov/media/137564/download
   Google Scholar
• Ugale, V. G., Patel, H. M., & Surana, S. J. (2017). Molecular modeling studies of quinoline derivatives as VEGFR-2 tyrosine kinase inhibitors using pharmacophore based 3-D QSAR and docking approach. The Arabian Journal of Chemistry, 10, 1980–2003.
   Web of Science ®Google Scholar
• Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005). Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology Journal, 2, 69. https://doi.org/10.1186/1743-422X-2-69
   PubMed Web of Science ®Google Scholar
• Wang, J. (2020). Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. Journal of Chemical Information and Modeling, 60(6), 3277–3286. https://doi.org/10.1021/acs.jcim.0c00179
   PubMed Web of Science ®Google Scholar
• Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269–277. https://doi.org/10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., Larson, N., Strickley, R., Wells, J., Stuthman, K. S., Van Tongeren, S. A., Garza, N. L., Donnelly, G., Shurtleff, A. C., Retterer, C. J., … Bavari, S. (2016). Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature, 531(7594), 381–385. https://doi.org/10.1038/nature17180
   PubMed Web of Science ®Google Scholar
• WHO. (2021a). WHO coronavirus disease (COVID-19) dashboard. Retrieved June 18, 2021, from https://who.sprinklr.com/
   Google Scholar
• WHO. (2021b). World Health Organization website. Retrieved June 18, 2021, from https://www.who.int/
   Google Scholar
• Zhang, L., & Zhou, R. (2020). Binding mechanism of remdesivir to SARS-CoV-2 RNA Dependent RNA Polymerase, preprints. https://doi.org/10.20944/preprints202003.0267.v1
   Google Scholar
• Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science (New York, N.Y.), 368(6489), 409–412. https://doi.org/10.1126/science.abb3405
   PubMed Web of Science ®Google Scholar
• Zhang, W., Pei, J., & Lai, L. (2017). Computational multitarget drug design. Journal of Chemical Information and Modeling, 57(3), 403–412. https://doi.org/10.1021/acs.jcim.6b00491
   PubMed Web of Science ®Google Scholar